程序性死亡受体1抑制剂治疗晚期肺癌患者的临床疗效和安全性

Clinical efficacy and safety of programmed cell death 1 inhibitor in the treatment of patients with advanced lung cancer

目的探讨程序性死亡受体1(PD-1)抑制剂治疗晚期肺癌患者的临床疗效和安全性。方法根据治疗方法的不同将80例晚期肺癌患者分为对照组和观察组,每组40例,对照组患者予以紫杉醇脂质体/培美曲塞+铂类治疗,观察组患者在对照组的基础上予以替雷利珠单抗治疗。比较两组患者的临床疗效、血清肿瘤标志物[糖类抗原125(CA125)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)]水平、健康状态(卡氏功能状态评分)及不良反应发生率。结果观察组患者的客观缓解率高于对照组,差异有统计学意义(P﹤0.05)。治疗后,两组患者的CEA、CA125、CA19-9水平均低于本组治疗前,观察组患者的CEA、CA125、CA19-9水平均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,观察组患者的卡氏功能状态评分明显高于对照组,差异有统计学意义(P﹤0.01)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论PD-1抑制剂治疗晚期肺癌患者可提高临床疗效,降低血清肿瘤标志物水平,改善健康状态,且安全性较好。

Objective To investigate the clinical efficacy and safety of programmed cell death 1(PD-1)inhibitor in the treatment of patients with advanced lung cancer.Method A total of 80 patients with advanced lung cancer were di-vided into control group and observation group according to different treatment methods,with 40 cases in each group,pa-tients in the control group were treated with paclitaxel liposome/pemetrexed+platinum,and patients in the observation group were treated with tislelizumab on the basis of the control group.The clinical efficacy,serum tumor markers[carbo-hydrate antigen 125(CA125),carcinoembryonic antigen(CEA)and carbohydrate antigen 19-9(CA19-9)]levels,health status(Karnofsky performance status score)and incidence of adverse reactions were compared between the two groups.Result The objective response rate of the observation group was higher than that of the control group(P<0.05).After treatment,the CEA,CA125 and CA19-9 levels in the two groups were lower than those before treatment,with lower lev-els in the observation group than those in the control group(P<0.05).After treatment,the Karnofsky performance status score of the observation group was significantly higher than that of the control group(P<0.01).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion PD-1 inhibitor can improve the clinical efficacy,reduce serum tumor marker levels,and improve health status in patients with advanced lung cancer,with higher safety.